The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Acetylation control of the retinoblastoma tumour-suppressor protein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“The activity of pRb is governed at the post-translational level by CDKs, principally cyclinD/Cdk4 and cyclinE/Cdk2, which sequentially phosphorylate pRb as cells progress towards S phas”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Yao, T.-P., Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., & Eckner, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81165-4 · Cited by 1,014
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694
Cited by
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Shaping the nuclear action of NF-κB
Chen, L.-F., & Greene, W. C. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1368 · Cited by 1,221
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
Self-citationCellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Minireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Iyer, N. G., Özdag, H., & Caldas, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207118 · Cited by 638
The Mammalian SIR2α Protein Has a Role in Embryogenesis and Gametogenesis
McBurney, M. W., Yang, X., Jardine, K., Hixon, M., Boekelheide, K., Webb, J. R., Lansdorp, P. M., & Lemieux, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.38-54.2003 · Cited by 611
“In mammals, a large number of nuclear proteins in addition to histones are acetylated (44), and in the cases of some important nuclear proteins such as retinoblastoma (11) and p53 (38, 51), it is thought that acetylation plays a role in regulating the function of these transcription regulators.”
BackgroundAcetylation of the C Terminus of Ku70 by CBP and PCAF Controls Bax-Mediated Apoptosis
Cohen, H. Y., Lavu, S., Bitterman, K. J., Hekking, B., Imahiyerobo, T. A., Miller, C., Frye, R., Ploegh, H., Kessler, B. M., & Sinclair, D. A. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00094-2 · Cited by 578
Molecular mechanisms underlying RB protein function
Dick, F. A., & Rubin, S. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3567 · Cited by 569
CtBP, an Unconventional Transcriptional Corepressor in Development and Oncogenesis
Chinnadurai, G. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00443-4 · Cited by 523
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
Yang, X.-J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh252 · Cited by 515
Antitumor Activity of a Small-Molecule Inhibitor of Human Silent Information Regulator 2 Enzymes
Heltweg, B., Gatbonton, T., Schuler, A. D., Posakony, J., Li, H., Goehle, S., Kollipara, R., DePinho, R. A., Gu, Y., Simon, J. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3617 · Cited by 469
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
RB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Acetylation inactivates the transcriptional repressor BCL6
Bereshchenko, O. R., Gu, W., & Dalla-Favera, R. (2002) · Nature Genetics · doi:10.1038/ng1018 · Cited by 394
Postigo, A. A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg226 · Cited by 387
Chk2 activates E2F-1 in response to DNA damage
Stevens, C., Smith, L., & La Thangue, N. B. (2003) · Nature Cell Biology · doi:10.1038/ncb974 · Cited by 385
Self-citationModulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Yu, X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.504 · Cited by 360
Lysine acetylation and the bromodomain: a new partnership for signaling
Yang, X. (2004) · BioEssays · doi:10.1002/bies.20104 · Cited by 357
Bouras, T., Fu, M., Sauve, A. A., Wang, F., Quong, A. A., Perkins, N. D., Hay, R. T., Gu, W., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408748200 · Cited by 355
Identification of a small molecule inhibitor of Sir2p
Bedalov, A., Gatbonton, T., Irvine, W. P., Gottschling, D. E., & Simon, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261574398 · Cited by 346
Molecular mechanisms of E2F-dependent activation and pRB-mediated repression
Frolov, M. V., & Dyson, N. J. (2004) · Journal of Cell Science · doi:10.1242/jcs.01227 · Cited by 338
Bakay, M., Wang, Z., Melcon, G., Schiltz, L., Xuan, J., Zhao, P., Sartorelli, V., Seo, J., Pegoraro, E., Angelini, C., et al. (2006) · Brain · doi:10.1093/brain/awl023 · Cited by 331
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Modulation of allostery by protein intrinsic disorder
Ferreon, A. C. M., Ferreon, J. C., Wright, P. E., & Deniz, A. A. (2013) · Nature · doi:10.1038/nature12294 · Cited by 314
Adenovirus-5 E1A: paradox and paradigm
Frisch, S. M., & Mymryk, J. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm827 · Cited by 308
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Nonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S.-W. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 300
Caron, C., Boyault, C., & Khochbin, S. (2005) · BioEssays · doi:10.1002/bies.20210 · Cited by 291
Henley, S. A., & Dick, F. A. (2012) · Cell Division · doi:10.1186/1747-1028-7-10 · Cited by 281
Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277
Chen, L.-F., & Greene, W. C. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0469-0 · Cited by 275
Differential regulation of E2F1 apoptotic target genes in response to DNA damage
Pediconi, N., Ianari, A., Costanzo, A., Belloni, L., Gallo, R., Cimino, L., Porcellini, A., Screpanti, I., Balsano, C., Alesse, E., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb998 · Cited by 266
Histone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Huang, S.-M., & McCance, D. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.17.8710-8721.2002 · Cited by 151
Munro, J., Barr, N. I., Ireland, H., Morrison, V., & Parkinson, E. K. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.017 · Cited by 141
RB, the conductor that orchestrates life, death and differentiation
Khidr, L., & Chen, P.-L. (2006) · Oncogene · doi:10.1038/sj.onc.1209612 · Cited by 123
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
Interaction of the HPV E7 proteins with the pCAF acetyltransferase
Avvakumov, N., Torchia, J., & Mymryk, J. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206562 · Cited by 107
Dick, F. A. (2007) · Cell Division · doi:10.1186/1747-1028-2-26 · Cited by 79
SUV39H1 interacts with AML1 and abrogates AML1 transactivity: AML1 is methylated in vivo.
Chakraborty, S., Sinha, K. K., Senyuk, V., & Nucifora, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206600 · Cited by 71
DNA‐damage‐responsive acetylation of pRb regulates binding to E2F‐1
Markham, D., Munro, S., Soloway, J., O'Connor, D. P., & La Thangue, N. B. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400591 · Cited by 62
The Retinoblastoma Gene Family in Cell Cycle Regulation and Suppression of Tumorigenesis
Dannenberg, J.-H., & te Riele, H. P. J. (2006) · Results and Problems in Cell Differentiation · doi:10.1007/400_002 · Cited by 47
Role of the retinoblastoma tumor suppressor protein in cellular differentiation
Nguyen, D. X., & McCance, D. J. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20375 · Cited by 40
Metadata
- Authors
- Chan, H. M., Krstic-Demonacos, M., Smith, L., Demonacos, C., & Thangue, N. B. L.
- Venue
- Nature Cell Biology
- Published
- 2001-06-18
- Volume
- 3
- Issue
- 7
- Pages
- 667-674
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W1602446144
- Cited by
- 282
- References
- 40
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.